218 related articles for article (PubMed ID: 32894760)
21. GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis.
Koller PB; Zhang H; Kantarjian H; Jabbour E; Pierce S; Gocho Y; Roberts KG; Yang W; Mullighan CG; Yang J; Konopleva M; Jain N
Am J Hematol; 2021 Mar; 96(3):E71-E74. PubMed ID: 33275800
[No Abstract] [Full Text] [Related]
22. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.
Patel B; Rai L; Buck G; Richards SM; Mortuza Y; Mitchell W; Gerrard G; Moorman AV; Duke V; Hoffbrand AV; Fielding AK; Goldstone AH; Foroni L
Br J Haematol; 2010 Jan; 148(1):80-9. PubMed ID: 19863538
[TBL] [Abstract][Full Text] [Related]
24. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.
de Haas V; Oosten L; Dee R; Verhagen OJ; Kroes W; van den Berg H; van der Schoot CE
Br J Haematol; 2000 Dec; 111(4):1080-6. PubMed ID: 11167743
[TBL] [Abstract][Full Text] [Related]
26. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
[TBL] [Abstract][Full Text] [Related]
27. Genomic ancestry and somatic alterations correlate with age at diagnosis in Hispanic children with B-cell acute lymphoblastic leukemia.
Walsh KM; de Smith AJ; Welch TC; Smirnov I; Cunningham MJ; Ma X; Chokkalingam AP; Dahl GV; Roberts W; Barcellos LF; Buffler PA; Metayer C; Wiemels JL
Am J Hematol; 2014 Jul; 89(7):721-5. PubMed ID: 24753091
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
29. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
[TBL] [Abstract][Full Text] [Related]
30. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
31. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia.
Orgel E; Tucci J; Alhushki W; Malvar J; Sposto R; Fu CH; Freyer DR; Abdel-Azim H; Mittelman SD
Blood; 2014 Dec; 124(26):3932-8. PubMed ID: 25349177
[TBL] [Abstract][Full Text] [Related]
32. Inherited GATA3 variant associated with positive minimal residual disease in childhood B-cell acute lymphoblastic leukemia via asparaginase resistance.
Li C; Liang W; He Y; Zhao X; Qian J; Li Z; Jiang C; Zheng Q; Fu X; Zhang W; Liu H; Sun X; Qian M; Zhang H
Clin Transl Med; 2021 Aug; 11(8):e507. PubMed ID: 34459144
[No Abstract] [Full Text] [Related]
33. Risk Factors for Relapse of Childhood B Cell Acute Lymphoblastic Leukemia.
Zhang R; Zhu H; Yuan Y; Zhao J; Yang X; Tian Z
Med Sci Monit; 2020 Jul; 26():e923271. PubMed ID: 32619211
[TBL] [Abstract][Full Text] [Related]
34. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
35. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.
Willemse MJ; Seriu T; Hettinger K; d'Aniello E; Hop WC; Panzer-Grümayer ER; Biondi A; Schrappe M; Kamps WA; Masera G; Gadner H; Riehm H; Bartram CR; van Dongen JJ
Blood; 2002 Jun; 99(12):4386-93. PubMed ID: 12036866
[TBL] [Abstract][Full Text] [Related]
36. Effect of
Chu X; Qian M; Yang J; Wu D; Gao J; Cao L; Fang F; Pan J; Zhang H; Hu S
Front Pediatr; 2022; 10():1044866. PubMed ID: 36714653
[TBL] [Abstract][Full Text] [Related]
37. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.
Xu H; Yang W; Perez-Andreu V; Devidas M; Fan Y; Cheng C; Pei D; Scheet P; Burchard EG; Eng C; Huntsman S; Torgerson DG; Dean M; Winick NJ; Martin PL; Camitta BM; Bowman WP; Willman CL; Carroll WL; Mullighan CG; Bhojwani D; Hunger SP; Pui CH; Evans WE; Relling MV; Loh ML; Yang JJ
J Natl Cancer Inst; 2013 May; 105(10):733-42. PubMed ID: 23512250
[TBL] [Abstract][Full Text] [Related]
38. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.
Xu H; Cheng C; Devidas M; Pei D; Fan Y; Yang W; Neale G; Scheet P; Burchard EG; Torgerson DG; Eng C; Dean M; Antillon F; Winick NJ; Martin PL; Willman CL; Camitta BM; Reaman GH; Carroll WL; Loh M; Evans WE; Pui CH; Hunger SP; Relling MV; Yang JJ
J Clin Oncol; 2012 Mar; 30(7):751-7. PubMed ID: 22291082
[TBL] [Abstract][Full Text] [Related]
39. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
Eckert C; Groeneveld-Krentz S; Kirschner-Schwabe R; Hagedorn N; Chen-Santel C; Bader P; Borkhardt A; Cario G; Escherich G; Panzer-Grümayer R; Astrahantseff K; Eggert A; Sramkova L; Attarbaschi A; Bourquin JP; Peters C; Henze G; von Stackelberg A;
J Clin Oncol; 2019 Dec; 37(36):3493-3506. PubMed ID: 31644328
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
